Colgate Tops Q2 Earnings & Sales Estimates, Tweaks Organic Sales View
CL beats Q2 earnings and sales estimates on pricing and organic growth but narrows the full-year organic sales view to the low end of the 2-4% range.
Nonfarm Payrolls Come in SIgnificantly Below Expectations
Nonfarm Payrolls Come in SIgnificantly Below Expectations.
Compared to Estimates, Colgate-Palmolive (CL) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Colgate-Palmolive (CL) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Colgate-Palmolive (CL) Q2 Earnings and Revenues Beat Estimates
Colgate-Palmolive (CL) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.91 per share a year ago.
Colgate Q2 Earnings: Do Productivity Initiatives Suggest a Beat?
CL's Q2 results are likely to reflect benefits from pricing, innovation and gross margin gains amid inflation and foreign exchange headwinds.
Countdown to Colgate-Palmolive (CL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Colgate-Palmolive (CL) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts Estimate Colgate-Palmolive (CL) to Report a Decline in Earnings: What to Look Out for
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Colgate-Palmolive (CL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Colgate's Pricing Strength Keep Earnings Buoyant in 2025?
CL's strategic pricing, margin gains and productivity moves support steady EPS growth into 2025 despite cost pressures.
Colgate Taps Productivity Plan, Enhances Profits, Protects Margins
CL streamlines supply chain, modernizes manufacturing and cuts overhead to boost efficiency and execution.
Colgate-Palmolive: The Defensive Growth Case Is Delivering
Colgate-Palmolive is now fairly valued at 24x forward PE, offering a solid entry point for long-term investors seeking stability and steady growth. The company maintains dominant global market share in core segments and is expanding in pet nutrition, positioning it well for post-industry-bottom recovery. Recent results show resilient organic growth despite macro headwinds, with management expecting stabilization and a return to growth by year-end.
Momentum in Pet Business: A Catalyst for CL's Growth Phase?
Colgate sharpens its competitive edge in pet care, aiming to seize more market share.
